Entrada Therapeutics Reported Positive DMD Study Data
The Phase 1/2 trial for ENTR-601-45 met safety objectives in the first cohort of study participants.
Updated on Oct. 14, 2026 in Diabetes
Live Poll
Should the development of new genetic treatments for rare diseases be prioritized despite the inherent risks?
Entrada Therapeutics announced positive results for its ENTR-601-45 clinical study in Duchenne muscular dystrophy patients. All eight participants in the first cohort have transitioned to the open-label phase of the trial.
Why it matters
The experimental treatment is designed to restore the mRNA reading frame for patients with specific gene mutations. The trial aims to provide a therapeutic option for the estimated 9% of Duchenne patients amenable to exon 45 skipping.
Cohort 1 participants received three doses of 5 mg/kg, which met safety and tolerability objectives. The company plans to escalate dosing to 10 mg/kg for the second cohort and up to 15 mg/kg for the third cohort.
The players
Entrada Therapeutics
A biotechnology company headquartered in Boston that focuses on developing intracellular therapeutics for patients with rare diseases.
The details
Participants were administered intravenous doses on days one, 43, and 85, with muscle biopsies taken at screening and six weeks after the final dose. The study currently involves participants across clinical sites in the U.K. and EU.
Timeline
On October 14, 2026, Entrada Therapeutics released positive topline results for the study's first cohort.
Clinical data for the 10 mg/kg dose cohort is expected in the first half of 2027.
Health Landscape
This study contributes to the expanding field of genetic therapies designed to address the underlying causes of Duchenne muscular dystrophy. It represents a targeted approach within the broader landscape of treatments currently being researched for the approximately 41,000 individuals living with the condition in the U.S. and Europe.
This early-stage data indicates that the intravenous administration method was tolerated by participants, though it does not yet change standard clinical treatment. Families impacted by Duchenne muscular dystrophy should consult with their providers regarding enrollment in future clinical trials.
The takeaway
The study demonstrates that the 5 mg/kg dose level met necessary safety and tolerability objectives in early participants. Continued monitoring of higher dose cohorts will be required to determine if the treatment results in significant improvements in dystrophin production.
What happens next
Entrada Therapeutics expects to report clinical data from the second cohort of the study during the first half of 2027.
Further reading
Learn more about the latest research and advancements in Diabetes.
Live Poll
Should the development of new genetic treatments for rare diseases be prioritized despite the inherent risks?
